Peter Bains, MD & CEO of Syngene International, joins 24/7 Biopharma to discuss the company’s global CRDMO model, growing clinical trial capabilities in India, and its U.S. expansion through the Bayview facility in Baltimore. He highlights Syngene’s end-to-end R&D support for both small and large molecules, its 6,000-strong scientific team, and its work with 75% of the top 25 pharma companies. Bains also highlights SynVent, Syngene’s integrated discovery engine, as a key driver of early-stage biotech partnerships and future growth.
TWENTYFOURSEVENBIOPHARMA